Dutasteride is FDA-approved for bph/">benign prostatic hyperplasia only, and no topical dutasteride product is FDA-approved at any strength, so every use described on this page is off-label and depends on a compounded preparation. Topical dutasteride is an investigational approach to androgenetic alopecia that delivers the drug directly to the scalp, with the aim of suppressing DHT at the hair follicle while limiting systemic exposure. In a 2025 Phase II trial (Panuganti VK et al., Cureus 2025;17(8):e89309), topical dutasteride at 0.01%, 0.02% and 0.05% produced dose-dependent increases in target area hair count and hair width over 24 weeks, and no irritation was reported in the active treatment groups.
Why Topical?
The primary motivation for topical dutasteride is reducing systemic exposure. Oral dutasteride 0.5 mg/day lowers serum DHT by a median of 94% at one year, according to the FDA label, and systemic DHT suppression is the presumed mechanism behind the sexual adverse reactions that label lists. By applying dutasteride directly to the scalp, the aim is to suppress DHT at the follicle while limiting how much drug reaches the bloodstream.
Available Concentrations
| Concentration | Evidence Level | Notes |
|---|---|---|
| 0.01% | Phase II trial (2025) | Lowest studied dose, minimal systemic absorption |
| 0.02% | Phase II trial (2025) | Intermediate dose |
| 0.05% | Phase II trial (2025) | Highest studied dose, greatest efficacy |
| 0.1% | No randomized trial evidence | Above the highest concentration studied in the 2025 Phase II trial |
0.01% guide · 0.05% guide · Efficacy data
How to Get Topical Dutasteride
Topical dutasteride is not commercially available as an FDA-approved product. It is available through compounding pharmacies with a prescription. Some international pharmacies also offer topical formulations. Where to buy topical dutasteride · Compounding information.
2025 Phase II Trial Summary
The 2025 Phase II trial randomized 135 men aged 20 to 60 with androgenetic alopecia to topical dutasteride 0.01%, 0.02% or 0.05%, to oral finasteride 1 mg, or to placebo, once daily for 24 weeks. Target area hair count within 1 cm² at the vertex rose by 32.32 hairs on 0.01%, 27.48 on 0.02% and 75.52 on 0.05%, against 41.21 on oral finasteride 1 mg and 0.07 on placebo. The 0.05% solution beat oral finasteride on that endpoint (p = 0.0083). The investigators reported no significant change in serum testosterone or DHT in any dutasteride group at week 12 or week 24. Full trial analysis.
Dutasteride for hair loss · Side effects · Dutasteride vs finasteride
Sources
- Panuganti VK, et al. A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia. Cureus. 2025;17(8):e89309. PMC12405733
- FDA. Avodart (dutasteride) prescribing information, section 12.2. accessdata.fda.gov